Drink product and use thereof

Abstract

A drink product having pharmaceutical compositions as an active ingredients of, at least one phosphorylated inositol, optionally Genistein, optionally Ubiquinol, and optionally additional unphosphorylated inositol. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed.

1 - 52 . (canceled) 
     
     
         53 . An aqueous liquid formulation comprising:
 (a) water and   (b) at least one phosphorylated member selected from the group consisting of phosphorylated myoinositol having from one to nine phosphate groups inclusive of pyrophosphate groups in which each pyrophosphate is counted as two of the one to nine phosphate groups and/or an optical isomer of said phosphorylated myoinositol, and/or an orally acceptable salt thereof,   (c) optionally Genistein   (d) optionally Ubiquinol, in an orally absorbable form   (e) further optionally comprising one or more components selected from the group consisting of:
 (1) an unphosphorylated member selected from myoinositol and/or an optical isomer thereof, 
 (2) an orally acceptable free radical scavenger other than either of Genistein and Ubiquinol 
 (3) a nutritionally acceptable orally administrable electrolyte; 
 (4) a nutritionally acceptable orally administrable vitamin; 
 (5) a flavor; 
 (6) an orally administrable coloring agent; 
 (7) an orally administrable sweetener; 
 (8) an oral formulation acceptable thickener; 
 (9) an orally administrable, liquid formulation processing aid; and 
 (10) an orally administrable, liquid formulation auxiliary carrier other than water. 
   
     
     
         54 . The formulation of  claim 53  wherein the at least one phosphorylated member is selected from a tetramonophosphate, a pentamonophosphate, a hexamonophosphate, a pentamonophospho-monopyrophosphate, and a tetramonophospho-dipyryophosphate of (a) myoinositol or (b) an optical isomer of myoinositol. 
     
     
         55 . The formulation of  claim 53  wherein when said unphosphorylated inositol or optical isomer thereof is present, it is in the form of the inositol isomer that is present in at least one of the phosphorylated members when such phosphorylated members are viewed without consideration of the phosphorylations involved. 
     
     
         56 . The formulation of  claim 53  wherein when the unphosphorylated inositol or optical isomer thereof is present, it is selected from those members having a different inositol isomeric form from that in any of the phosphorylated members that are present when such phosphorylated members are viewed without consideration of the phosphorylations involved. 
     
     
         57 . A method of reducing the risk of damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 53 . 
     
     
         58 . A method of preventing damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of claim  531 . 
     
     
         59 . A method of treating damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of  claim 53 . 
     
     
         60 . A method of reducing the risk of developing HIV and/or AIDS and secondary cancers related to HIV and AIDS comprising orally administering the formulation of  claim 53 . 
     
     
         61 . The method of  claim 60  wherein said cancers related to HIV and AIDS is selected from Kaposi sarcoma and non-Hodgkin lymphoma, Hodgkin disease and cancers of the lung, mouth, skin, cervix, and digestive system, liver, blood, soft tissue, and muscular tumors. 
     
     
         62 . A method of preventing a HIV/AIDS related cancer selected from breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, colon cancer liver, cervical, uterine, liver, blood, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of  claim 53 . 
     
     
         63 . A method of treating a cancer selected from Kaposi sarcoma and non-Hodgkin lymphoma, other AIDS-related cancers selected from Hodgkin disease and cancers of the lung, mouth, skin, cervix, and digestive system, liver, blood, soft tissue, and muscular tumors breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, colon cancer liver, cervical, uterine, liver, blood, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of  claim 53 . 
     
     
         64 . A method of increasing T cells and or inhibiting HIV related CD4 reduction comprising administering the composition of  claim 53  to a subject in need thereof. 
     
     
         65 . A method for blocking the communication between a HIV cell surface to internal cellular compartment comprising administering the composition of  claim 53  to a subject in need thereof. 
     
     
         66 . A method for preventing an HIV particle from entering the internal cellular compartments thereby preventing the spread of the infection comprising administering the composition of  claim 53  to a subject in need thereof. 
     
     
         67 . A method of reducing the risk of adverse effects of common and current drug toxicities' associated with current anti-viral therapies comprising administering the composition of  claim 53  to a subject in need thereof. 
     
     
         68 . A method of reducing drug resistance known to occur with current drugs because it's a plant based product comprising administering the composition of  claim 53  to a subject in need thereof. 
     
     
         69 . A method for both prevention HIV infection of resting CD4 T-cells, viral DNA synthesis, and/or viral nuclear migration comprising administering the composition of  claim 53  to a subject in need thereof. 
     
     
         70 . A method for preventing Gag-NA chaperone, inositol does that interaction prior to membrane binding in HIV comprising administering the composition of  claim 53  to a subject in need thereof. 
     
     
         71 . A method for inhibiting the replication of HIV-1 comprising administering the composition of  claim 53  to a subject in need thereof. 
     
     
         72 . A method for AP3B1 regulation and HIV-1 Gag release comprising administering the composition of  claim 53  to a subject in need thereof.